MedWatch

Pfizer to acquire Reviral as RSV race continues

The proposed USD 525m acquisition includes therapeutic candidates within the RSV indication, which Bavarian Nordic is also targeting.

Photo: CARLO ALLEGRI/REUTERS / X90181

Pharmaceutical giant Pfizer is continuing to expand its efforts within the RSV indication, fresh off success with its Covid-19 vaccine.

Now, this has led the firm to enter into an acquisition agreement with biopharmaceutical firm Reviral, which develops antiviral treatments for respiratory syncytial virus (RSV).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs